Related Experiment Videos
Monocyte-mediated drug-dependent cellular cytotoxicity: effects on different WEHI 164 target cell lines
Abstract:
The contribution of monocyte cytotoxic protein factor (CF) to monocyte-mediated drug-dependent cellular cytotoxicity (DDCC) has been investigated. Cell lines which have been derived from murine WEHI 164 cells (termed WEHI 164 parental) by selecting for high (WEHI 164 clone 3) and low (R-WEHI 164) sensitivity to CF-mediated cytotoxicity were used as target cells in DDCC. By comparing the CF doses which produced 50% dead cells (LD 50) we found that WEHI 164 clone 3 was approximately 30 times more sensitive than WEHI 164 parental which in turn was 70 times more sensitive than R-WEHI 164. Actinomycin D (Act D) treatment of WEHI 164 parental and R-WEHI 164 greatly increase susceptibility to CF-mediated cytotoxicity. The susceptibility of WEHI 164 clone 3 was apparently somewhat increased at low dilutions of CF, whereas no significant increase was observed at high dilutions. The susceptibility to DDCC of the three target cell lines (WEHI 164 parental, WEHI 164 clone 3, and R-WEHI 164) correlated with the sensitivity pattern obtained in CF-mediated cytotoxicity of Act D-treated target cells. Monocyte- and CF-mediated cytotoxicity against Act D-treated WEHI 164 clone 3 and R-WEHI 164 was inhibited by neutralizing CF antiserum. These data indicate that CF is an effector molecule in monocyte-mediated DDCC.
Insights
Monocyte cytotoxic protein factor (CF) contributes to drug-dependent cellular cytotoxicity (DDCC). This study shows CF is an effector molecule in monocyte-mediated DDCC, particularly when target cells are treated with Actinomycin D.
Area of Science:
- Immunology
- Cell Biology
- Molecular Medicine
Background:
- Monocyte-mediated drug-dependent cellular cytotoxicity (DDCC) is a crucial immune mechanism.
- The specific role of monocyte cytotoxic protein factor (CF) in DDCC has not been fully elucidated.
- Understanding CF's contribution is vital for deciphering monocyte-mediated cytotoxic pathways.
Purpose of the Study:
- To investigate the contribution of monocyte cytotoxic protein factor (CF) to monocyte-mediated DDCC.
- To determine if CF acts as an effector molecule in DDCC.
- To assess the impact of Actinomycin D (Act D) on target cell sensitivity to CF and DDCC.
Main Methods:
- Utilized murine WEHI 164 cell lines with varying sensitivities to CF-mediated cytotoxicity (WEHI 164 parental, clone 3, and R-WEHI 164) as target cells.
- Assessed target cell susceptibility to CF-mediated cytotoxicity and DDCC.
- Investigated the effect of Actinomycin D (Act D) treatment on target cell sensitivity.
- Employed neutralizing CF antiserum to inhibit monocyte- and CF-mediated cytotoxicity.
Main Results:
- WEHI 164 clone 3 cells were approximately 30 times more sensitive to CF than WEHI 164 parental cells, which were 70 times more sensitive than R-WEHI 164 cells.
- Actinomycin D treatment significantly increased the susceptibility of WEHI 164 parental and R-WEHI 164 cells to CF-mediated cytotoxicity.
- The susceptibility of target cells to DDCC correlated with their sensitivity to CF-mediated cytotoxicity after Act D treatment.
- Neutralizing CF antiserum inhibited monocyte- and CF-mediated cytotoxicity against Act D-treated cells.
Conclusions:
- Monocyte cytotoxic protein factor (CF) is an effector molecule in monocyte-mediated DDCC.
- Target cell susceptibility to CF and DDCC is enhanced by Actinomycin D treatment.
- These findings clarify the role of CF in monocyte-mediated immune responses.